In the drug and alcohol treatment field, what works for one person may not work for another; and sometimes more than one type of treatment may be necessary for successful recovery. Now, there are medications for certain addictions, which can offer treatment for some people.
Over the past 30 years, the Matrix Institute has participated in research investigating new medications for addictions. We’re proud to say that we have been a part of the research that has resulted in the availability of medications for alcohol and opioid dependence. Matrix has functioned as a clinical site in collaboration with researchers from UCLA, NIDA, CTN, and private industry.
We have also participated in many multi-site trials, funded by the National Institute on Drug Abuse. The trials studied various medications for stimulant dependence and we remain steadfastly dedicated to finding one.
The most recent trial we participated in was completed with nine other sites, including the University of Pennsylvania and Columbia University, as well as sites in San Diego, Denver, Baltimore, Albuquerque, Cincinnati, Houston and Salt Lake City. This study looked at a medication (nepicastat) for cocaine dependence with the aim of reducing the pleasurable effects of cocaine and facilitating the cessation of use.
For a listing of peer-reviewed articles involving The Matrix Model, you may visit our PubMed Bibliography:
1993 Ritanserin for cocaine (Janssen Pharmaceuticals) WLA, SFV
1993 Naltrexone for alcohol (Dupont Pharmaceuticals) WLA, SFV
1994 Naltrexone plus Matrix for opiates (NIDA) WLA, SFV
1995 CBT & CM for cocaine (NIDA) WLA, SFV
1995 CBT & CM for stimulant-users on methadone (NIDA) LA
1996 Acamprosate for alcohol (Lipha Pharm.) WLA
1997 Evaluation of SP 39166 for cocaine (Shering-Plough Pharmaceuticals) WLA
1998 Methamphetamine Treatment Project: Matrix Model vs Treatment as Usual for Methamphetamine Dependence (CSAT) CM ** We achieved Evidence-based Treatment status as a result
2000 Naltrel for alcohol (Drug Abuse Sciences) WLA
2000 Office-based buprenorphine (NIDA) WLA
2000 ADL-8-2698 for opioid-induced GI dysfunction (Adolor Corporation) LA
2001 Viracept efficacy, safety, and PK with methadone (Agouron Pharmaceuticals) LA2002 Matrix & incentives vs Matrix only with methamphetamine users (NIDA-CTN) RC
2003 Double-blind, Placebo-Controlled Evaluation of Ondansetron for methamphetamine dependence (NIDA) CM
2003 Double-blind, Placebo-Controlled Evaluation of Bupropion for methamphetamine dependence (NIDA) CM
2004 Effective Adolescent Treatment (CSAT) MET/CBT-5 (our WLA BAT Program)
2004 Safer Sex Skills for Men in Outpatient Drug Treatment (NIDA-CTN) RC
2005 Gabapentin and pain tolerance in methadone patients (NIDA) LA
2006 Double-blind, Placebo-Controlled Evaluation of Topiramate for methamphetamine dependence (NIDA) CM
2007 Double-blind, Placebo-Controlled Evaluation of Modafinil for Methamphetamine (NIDA-VA) SFV
2007 Starting treatment with agonist replacement therapies (methadone and buprenorphine, NIDA) LA
2007-2010 Four models of telephone support in aftercare (NIDA) WLA, SFV, RC
2011 Double-blind, Placebo-Controlled Evaluation of vigabatrin for cocaine (NIDA-VA) LA2013-2015 Double-blind, Placebo-Controlled Evaluation of nepicastat for cocaine (NIDA)
2013-2015 Double-blind, Placebo-Controlled Evaluation of nepicastat for cocaine (NIDA)
LA = Los Angeles Clinic
WLA = West Los Angeles Clinic
SFV = San Fernando Valley Clinic (Woodland Hills)
RC = Rancho Cucamonga Clinic
Matrix Institute is available to participate as a clinical site for future clinical trials involving medication and/or psychosocial treatment for substance use disorders. We are also interested in research involving the Matrix Model for Adults, Adolescents, and Criminal Justice, and may provide Matrix Model materials to researchers wishing to investigate psychosocial addiction treatments.